The preliminary Q3 revenue beat and expected guidance raise are positive, but the EPS miss and CEO transition create near-term uncertainty. Watch the Q3 2026 earnings call for finalized guidance and any commentary on margin trajectory under the new leadership structure.
Price Chart
Executive Summary
NeoGenomics announced a planned CEO succession: President/COO Warren Stone will become CEO effective Jan 4, 2027, while current CEO Tony Zook transitions to Executive Chairman. The company also released preliminary Q3 2026 revenue of approximately $209M (+11% YoY) with NGS growth of ~28%, and expects to raise full-year revenue guidance at the midpoint. The leadership transition is orderly and the preliminary revenue beat is positive, but the EPS miss (-9.8% vs consensus) tempers the outlook.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue expected ~$209M, up ~11% YoY from $187M in Q3 2025
- NGS revenue growth of approximately 28% YoY
- EPS of $0.05 missed consensus of $0.06 (-9.8% miss)
- Full-year 2026 revenue guidance expected to increase at midpoint from current $797-$803M range
- Warren Stone (current President/COO) appointed CEO effective Jan 4, 2027
- Tony Zook transitions to Executive Chairman effective Jan 4, 2027
- Board Chair Lynn Tetrault to step down as Chair Jan 4, 2027, will not stand for reelection at 2027 annual meeting
- Michael Kelly appointed Lead Independent Director effective Jan 4, 2027
- Board size increased from 10 to 11 directors via bylaw amendment
Financial Impact
Preliminary Q3 revenue ~$209M vs $207.3M consensus; EPS $0.05 vs $0.06 consensus; full-year revenue guidance expected to be raised at midpoint
Risk Factors
- CEO transition creates execution risk through early 2027
- EPS miss vs consensus despite revenue beat suggests margin pressure
- Preliminary results are unaudited and subject to adjustment
- Board chair departure and bylaw amendment signal governance changes
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001077183-26-000069 |
| Exhibit: exhibit991-pressrelease.htm | 0001077183-26-000069 |
| Exhibit: exhibit31-amendmenttoamend.htm | 0001077183-26-000069 |
| Document: 0001077183-26-000069-index-headers.html | 0001077183-26-000069 |
| Document: 0001077183-26-000069-index.html | 0001077183-26-000069 |
| Document: 0001077183-26-000069.txt | 0001077183-26-000069 |
| 8-K Data (Synthetic) | 0001077183-26-000069 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $16.51 | awaiting T+60 | — | $16.69 (+1.12%) |
Jul 20, 2026 14w ago | 8-K | $14.45 $16.66 | ▲ +15.29% | ▲ +11.32% | $16.69 (+15.50%) |
May 22, 2026 22w ago | 8-K | $9.27 $16.66 | ▲ +79.67% | ▲ +76.94% | $16.69 (+80.04%) |
Apr 28, 2026 25w ago | 8-K | $8.96 $13.89 | ▲ +55.02% | ▲ +50.91% | $16.69 (+86.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers